Recce Pharmaceuticals Ltd (RCE.AX)
| Previous close | 0.6100 |
| Open | 0.6100 |
| Bid | 0.5950 x 55200 |
| Ask | 0.6300 x 1644700 |
| Day's range | 0.5950 - 0.6250 |
| 52-week range | 0.4100 - 0.7772 |
| Volume | |
| Avg. volume | 164,298 |
| Market cap | 121.372M |
| Beta (5Y monthly) | 1.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial
First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future - 4,000mg highest dosage to date in this clinical trialRECCE® 327 (R327) tested at four fast IV infusion times (15-mins, 20-mins, 30-mins, 45-mins) over various dosage levelsMinimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples, a dose optimization exercise for regulatory purposes SYDNEY, Australia, May 17, 2024 (G
- GlobeNewswire
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
RECCE® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery methodR327 is being evaluated for potential use to treat ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) SYDNEY, Australia, May 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced positive results from a precli
- GlobeNewswire
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “Copolymer and Method for Treatment of Bacterial Infection,” for its anti-infectives, with expiry in 2035. “We thank the China National Intellectual Property Administration for their recognition of the signific
